Home
European Pharmaceutical Pricing & Reimbursement
21 October - 22 October 2013
European Pharmaceutical Pricing & Reimbursement

We are pleased to announce our forthcoming European Pharmaceutical Pricing & Reimbursement conference on the 21 & 22 October. Now in its 19th year, this event has been one of the oldest market leaders in the pharmaceutical industries calendar for some time.


Our expert speaking faculty; made up from key industry personnel from big pharma, biotech and academia will thoroughly explain and offer advice on P&R and market access. The 2013 agenda will focus on European and US markets including country specific case studies proving strategic insight into how a wide range of complex issues can be readily adapted to.
 

Future product release requires a well thought out and cross sector integrated market access strategy - Economic value in product development is now paramount in reimbursement. Allow P&R 2013 to provide you with the most comprehensive up to date centre of information with reimbursement evidence in product development; Impact of HTA in different markets and international based price referencing.

How will value based pricing affect the economic market in the U.K? This long discussed format has a number of looming deadlines for progression and looks to be taking gradual steps forward, with new PPBS taking the fore in covering some products. See how these formats can affect your product and where exactly they will lead.

FEATURED SPEAKERS

Janice Haigh

Janice Haigh

Practice Leader, Market Access, Quintiles
Leslie Galloway

Leslie Galloway

Chairman, Ethical Medicines Industry Group
Peter Hertzman

Peter Hertzman

Nordic Market Access Director, Bristol Myers Squibb
Sarah Pitluck

Sarah Pitluck

Senior Director, Global Pricing & Reimbursement, Alexion Pharmaceuticals Inc

Anne-Toni Rodgers

Global Payer Lead, AstraZeneca
Anne-Toni Rodgers

Bertram Häussler

Director, IGES Institut.
Bertram Häussler

Ceri Phillips

Professor of Health Economics and Head of Swansea Centre for Health Economics, Swansea University
Ceri Phillips

Donald Macarthur

Global Pharmaceutical Business Analyst, JustPharmaReports
Donald Macarthur

Franz Pichler

Director, Global Public Policy, Eli Lilly & Co
Franz Pichler

Janice Haigh

Practice Leader, Market Access, Quintiles
Janice Haigh

Leslie Galloway

Chairman, Ethical Medicines Industry Group
Leslie Galloway

Nick Bosanquet

Professor of Health Policy, Imperial College London
Nick Bosanquet

Patrick Mollon

Director Health-Economics & Outcomes Research, Novartis
Patrick Mollon

Peter Hertzman

Nordic Market Access Director, Bristol Myers Squibb
Peter Hertzman

Sarah Pitluck

Senior Director, Global Pricing & Reimbursement, Alexion Pharmaceuticals Inc
Sarah Pitluck

Strati Sakellariou

Associate, White & Case LLP
Strati Sakellariou

Stratigoula Sakellariou

Associate, White & Case LLP
Stratigoula Sakellariou

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Introduction to HTA

clock

9:30

Understanding the HTA map

  • Key agencies
  • Types of assessment and evaluation
  • Differences and similarities
  • clock

    11:00

    Break for Coffee

    clock

    11:30

    HTA uncovered

  • Drivers of success and failure
  • What they don’t print in the rules
  • clock

    12:00

    Q&A

    clock

    12:30

    Close of Workshop

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Donald Macarthur

    Donald Macarthur, Global Pharmaceutical Business Analyst, JustPharmaReports

    clock

    9:10

    Value Based Pricing

    Leslie Galloway

    Leslie Galloway, Chairman, Ethical Medicines Industry Group

    Implications for PPRS
    What is outside the negotiations?
    How will value be measured?

    clock

    9:50

    Implications of requiring traditional health economic assessments when evaluating ultra-orphan drugs

    Sarah Pitluck

    Sarah Pitluck, Senior Director, Global Pricing & Reimbursement, Alexion Pharmaceuticals Inc

  • Traditional cost-effectiveness analyses are not an appropriate method to evaluate ultra-orphan drugs and can have a negative impact on patient access to treatments
  • Countries that require traditional economic analyses inappropriately disadvantage patients with ultra-rare diseases
  • Instead, review agencies should look at a combination of other factors when evaluating such drugs
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Establishment of the permanent pan-European HTA network: implications for HTA and coverage decision making

    Franz Pichler

    Franz Pichler, Director, Global Public Policy, Eli Lilly & Co

  • Timeline and process to the establishment of the network
  • The role of EUnetHTA in terms of operational implementing
  • Key activities proposed for the network and implications of these activities for pharma
  • clock

    11:40

    The challenge of value delivery

    Janice Haigh

    Janice Haigh, Practice Leader, Market Access, Quintiles

  • How do global value messages translate in the local environment?
  • What types of value messages best support local negotiations?
  • How do we make sure that the reimbursement price agreed at national level becomes the realised price at local level?
  • clock

    12:20

    Networking Lunch

    clock

    13:50

    Integration of Health-Economics and Market Access in the development of innovative drugs

    Patrick Mollon

    Patrick Mollon, Director Health-Economics & Outcomes Research, Novartis

  • Value-Based Development: need and opportunities to demonstrate value
  • Health-Economic strategies to anticipate Market Access needs
  • Methods and Tools supporting value evidence generation
  • clock

    14:30

    New Evidence on the Effectiveness Gap; How Pharma can deliver

    Nick Bosanquet

    Nick Bosanquet, Professor of Health Policy, Imperial College London

  • The current problem: case studies in COPD and cancer
  • International comparisons of the effectiveness gap—France,UK,Germany and Finland
  • Partnership with pharma and health services  to deliver therapeutic results
  • clock

    15:10

    Key learnings of 2 years of AMNOG

    Bertram Häussler

    Bertram Häussler, Director, IGES Institut.

  • Pricing and additional benefit
  • Do innovative drugs still have a chance?
  • Roadblocks moving forward
  • Case study
  • clock

    15:50

    Chairman’s Closing Remarks and Close of Day One

    clock

    16:00

    Afternoon Tea

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Donald Macarthur

    Donald Macarthur, Global Pharmaceutical Business Analyst, JustPharmaReports

    clock

    9:10

    The new NICE and its global network

    Anne-Toni Rodgers

    Anne-Toni Rodgers, Global Payer Lead, AstraZeneca

  • A new Leadership … a New NICE?
  • A UK Government Export  - understand how NICE proactively shapes the Pricing & Reimbursement environment internationally
  • Plan your global response
  • clock

    9:50

    Reform of the EU transparency directive

    Strati Sakellariou

    Strati Sakellariou, Associate, White & Case LLP

  • The push for reform – issues not covered in the 1989 Directive
  • The content and status of the reform proposal
  • Next steps – when the changes will take effect in practice
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    No-one benefits from flying with empty planes: What options do we have to improve access in oncology? Experiences from Scandinavia

    Peter Hertzman

    Peter Hertzman, Nordic Market Access Director, Bristol Myers Squibb

  • Patients are benefiting from many new and exciting innovative oncology products. However, the discrepancies between providers’ and payors’ expectations have still to be resolved.
  • There are various contractual options tested out in reality in order to resolve the discrepancies. What are the pros and cons with these options
  • Examples of the above from the Scandinavian markets
  • clock

    11:40

    Japan: The Land that Cost Containment Forgot

    Donald Macarthur

    Donald Macarthur, Global Pharmaceutical Business Analyst, JustPharmaReports

  • Pricing environment in Japan vs leading western countries
  • Price comparisons
  • Market entry strategies
  • Prospects for change
  • clock

    12:20

    Networking Lunch

    clock

    13:50

    Pricing of pharmaceuticals in a resource constrained environment

    Ceri Phillips

    Ceri Phillips, Professor of Health Economics and Head of Swansea Centre for Health Economics, Swansea University

  • Healthcare policies in a period of recession
  • Policies relating to pharmaceuticals during recessionary periods
  • New initiatives in pharmaceutical pricing
  • The role of HTA
  • clock

    14:30

    Panel Discussion:European Pricing & Reimbursement going forwards

    Leslie Galloway

    Leslie Galloway, Chairman, Ethical Medicines Industry Group

    Anne-Toni Rodgers

    Anne-Toni Rodgers, Global Payer Lead, AstraZeneca

    clock

    15:10

    Chairman’s Closing Remarks and Close of Day Two

    clock

    15:20

    Afternoon Tea


    Director
    IGES Institut.
    Global Payer Lead
    AstraZeneca
    Professor of Health Economics and Head of Swansea Centre for Health Economics
    Swansea University
    Nordic Market Access Director
    Bristol Myers Squibb
    Director Health-Economics & Outcomes Research
    Novartis
    Director, Global Public Policy
    Eli Lilly & Co
    Senior Director, Global Pricing & Reimbursement
    Alexion Pharmaceuticals Inc
    Practice Leader, Market Access
    Quintiles
    Chairman
    Ethical Medicines Industry Group
    Professor of Health Policy
    Imperial College London
    Global Pharmaceutical Business Analyst
    JustPharmaReports
    Associate
    White & Case LLP
    Associate
    White & Case LLP

    Workshops

    HTA Uncovered

    HTA Uncovered

    Holiday Inn Regents Park
    23 October 2013
    London, United Kingdom

    Holiday Inn Regents Park

    Carburton Street
    London W1W 5EE
    United Kingdom

    Holiday Inn Regents Park

    Choose the well-connected Holiday Inn London-Regent's Park hotel, with a superb central London location and speedy transport links. Holiday Inn London-Regent's Park is in a leafy and cosmopolitan area of central London, a 10-minute walk from bustling Oxford Street. Leave your car in our NCP managed underground car park, and explore London by Tube. Great Portland Street Tube station is 25 metres from the hotel, from where you can reach the City and Canary Wharf in 30 minutes, and London Heathrow Airport in 45 minutes.

    Wireless Internet is available throughout the hotel, and you can invite up to 300 people to events at the Academy Conference Centre, with an IT technician and break-out zones. Holiday Inn London-Regent's Park is a 10-minute walk from Santander's offices and businesses in the BT Tower. Stroll 5 minutes to Regent's Park, where you'll find London Zoo and pretty Primrose Hill. We're a 10-minute walk from Bond Street boutiques and 20 minutes from Buckingham Palace and cruises on the River Thames.

    Ask our Concierge to plan your day out and book West End theatre tickets. Room Service is available 24 hours at Holiday Inn London-Regent's Park, or dine in the vibrant Junction Restaurant. Our Junction Bar has a menu of light bites, and a hot breakfast buffet is served daily.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.